UCL  IRIS
Institutional Research Information Service
UCL Logo
Please report any queries concerning the funding data grouped in the sections named "Externally Awarded" or "Internally Disbursed" (shown on the profile page) to your Research Finance Administrator. Your can find your Research Finance Administrator at https://www.ucl.ac.uk/finance/research/rs-contacts.php by entering your department
Please report any queries concerning the student data shown on the profile page to:

Email: portico-services@ucl.ac.uk

Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
Publication Detail
Anti-TNF drives regulatory T cell expansion by paradoxically promoting membrane TNF-TNFRII binding in rheumatoid arthritis
Abstract
The interplay between inflammatory and regulatory pathways orchestrate an effective immune response that provides protection from pathogens whilst limiting injury to host tissue. TNF is a pivotal inflammatory cytokine but there is conflicting evidence as to whether it boosts or inhibits regulatory T cells (Treg). Here we show that the therapeutic anti-TNF antibody adalimumab, but not the soluble TNF receptor etanercept, paradoxically promoted the interaction between monocytes and Treg isolated from patients with rheumatoid arthritis (RA). Adalimumab bound to monocyte membrane TNF from RA patients and unexpectedly enhanced its expression but also its binding to TNFRII expressed on Treg. As a consequence adalimumab expanded functional Foxp3+ Treg equipped to suppress Th17 through an IL-2/STAT5 dependent mechanism. Our data not only highlight the beneficial effect of membrane TNF on Treg numbers during chronic inflammation but in addition reveals how a therapeutic antibody that is thought to act by simply blocking its target can enhance the regulatory properties of this pro-inflammatory cytokine.
Publication data is maintained in RPS. Visit https://rps.ucl.ac.uk
 More search options
UCL Researchers
University College London - Gower Street - London - WC1E 6BT Tel:+44 (0)20 7679 2000

© UCL 1999–2011

Search by